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Dapagliflozin and Diuretic Use in Patients With Heart Failure and
Reduced Ejection Fraction in DAPA-HF
Editorial, see p 1055
Alice M. Jackson, MBChB, Pooja Dewan, MBBS, Inder S. Anand, MD, Jan Bělohlávek, MD,
PhD, Olof Bengtsson, PhLic, Rudolf A. de Boer, MD, PhD , Michael Böhm, MD, PhD ,
David W. Boulton, PhD, Vijay K. Chopra, MD , David L. DeMets, PhD, Kieran F. Docherty,
MBChB, Andrej Dukát, MD, PhD, Peter J. Greasley, PhD, Jonathan G. Howlett, MD, Silvio E.
Inzucchi, MD, Tzvetana Katova, MD, PhD, Lars Køber, MD, DMSc, Mikhail N. Kosiborod, MD,
Anna Maria Langkilde, MD, PhD, Daniel Lindholm, MD, PhD , Charlotta E.A. Ljungman,
MD, PhD, Felipe A. Martinez, MD, Eileen O’Meara, MD, Marc S. Sabatine, MD, MPH, Mikaela
Sjöstrand, MD, PhD, Scott D. Solomon, MD, Sergey Tereshchenko, MD, PhD, Subodh
Verma, MD, PhD , Pardeep S. Jhund, MD, PhD , and John J.V. McMurray, MD
ABSTRACT:
BACKGROUND: In the DAPA-HF trial (Dapagliflozin and Prevention of Adverse-Outcomes in
Heart Failure), the sodium-glucose cotransporter 2 inhibitor dapagliflozin reduced the risk of
worsening heart failure and death in patients with heart failure and reduced ejection fraction. We
examined the efficacy and tolerability of dapagliflozin in relation to background diuretic treatment
and change in diuretic therapy after randomization to dapagliflozin or placebo.
METHODS: We examined the effects of study treatment in the following subgroups: no diuretic
and diuretic dose equivalent to furosemide <40, 40, and >40 mg daily at baseline. We examined
the primary composite end point of cardiovascular death or a worsening heart failure event and its
components, all-cause death and symptoms.
RESULTS: Of 4616 analyzable patients, 736 (15.9%) were on no diuretic, 1311 (28.4%) were on
<40 mg, 1365 (29.6%) were on 40 mg, and 1204 (26.1%) were taking >40 mg. Compared with
placebo, dapagliflozin reduced the risk of the primary end point across each of these subgroups:
hazard ratios were 0.57 (95% CI, 0.36–0.92), 0.83 (95% CI, 0.63–1.10), 0.77 (95% CI, 0.60–0.99),
and 0.78 (95% CI, 0.63–0.97), respectively (P for interaction=0.61). The hazard ratio in patients
taking any diuretic was 0.78 (95% CI, 0.68–0.90). Improvements in symptoms and treatment
toleration were consistent across the diuretic subgroups. Diuretic dose did not change in most
patients during follow-up, and mean diuretic dose did not differ between the dapagliflozin and
placebo groups after randomization.
CONCLUSIONS: The efficacy and safety of dapagliflozin were consistent across the diuretic
subgroups examined in DAPA-HF.
REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03036124.
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ecause sodium-glucose cotransporter 2 (SGLT2) reabsorbs sodium, in addition to glucose,
in the proximal renal tubule, SGLT2 inhibition leads to natriuresis, as well as an increase in
urinary glucose and accompanying water excretion.1 Consequently, SGLT2 inhibitors have a
diuretic action in healthy volunteers and in individuals with type 2 diabetes mellitus. Clearly, a
diuretic action might be beneficial in patients with heart failure and reduced ejection fraction
(HFrEF) but could also be a double-edged sword. Patients with HFrEF are usually treated with a
conventional diuretic, most often a loop diuretic. However, little is known about the effects of
adding an SGLT2 inhibitor in people treated with conventional diuretic therapy. It is possible that
SGLT2 inhibitors might augment the effect of conventional diuretics, with attendant risk of volume
depletion. Conversely, because the diuretic effect of SGLT2 inhibitors is modest, they may add
little, if anything, to the potent effect of loop diuretics (and the combination of a loop diuretic and a
mineralocorticoid receptor antagonist [MRA]). Alternatively, an intermediate possibility is that
SGLT2 inhibitors might have a diuretic-sparing effect in patients with HFrEF.
Kidney function is clearly another key consideration in patients with HFrEF, many of whom
have renal impairment. If there is significant augmentation of diuresis resulting from the addition of
an SGLT2 inhibitor to conventional therapy, this might lead to worsening kidney function through
volume depletion and decreased renal perfusion, especially in the setting of renin-angiotensin-
aldosterone system blockade. Conversely, because the glycosuric effect of SGLT2 inhibitors
© 2020 The Authors. Circulation is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health,
Inc. This is an open access article under the terms of the Creative Commons Attribution License, which permits use,




● Inhibition of the sodium-glucose cotransporter 2 in the proximal renal tubule results in natriuresis,
increased urinary glucose, and water loss.
● In the DAPA-HF trial (Dapagliflozin and Prevention of Adverse-Outcomes in Heart Failure), 84% of
patients randomized were treated with a conventional diuretic such as a loop or thiazide diuretic.
● Little is known about the safety and efficacy of combining treatment with a sodium-glucose
cotransporter 2 inhibitor and conventional diuretics in patients with heart failure and reduced ejection
fraction.
WHAT ARE THE CLINICAL IMPLICATIONS?
● Our findings show that treatment with dapagliflozin is safe and effective regardless of diuretic use or
diuretic dose.
● The majority of patients in the DAPA-HF trial did not change their diuretic dose throughout follow-up,
and although a decrease in diuretic dose was more frequent with dapagliflozin than with placebo, the
between-group difference was small.
● There was an elevation in hematocrit that persisted regardless of baseline diuretic dose and despite a
reduction in diuretic dose during follow-up, suggesting that mechanisms other than
hemoconcentration might, in part, account for this observation.
B
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diminishes as renal function declines, so might the diuretic action of these agents, rendering them
less effective in patients with HFrEF with chronic kidney disease.1
Therefore, understanding the interaction between the effects of SGLT2 inhibitors and diuretic
therapy is of fundamental importance to the use of SGLT2 inhibitors in HFrEF. The DAPA-HF trial
(Dapagliflozin and Prevention of Adverse-Outcomes in Heart Failure) demonstrated that SGLT2
inhibition reduced the risk of worsening HF or death resulting from cardiovascular causes
compared with placebo in patients with HFrEF.2 In DAPA-HF, 84% of patients were prescribed a
diuretic at baseline in addition to other standard therapy, including a renin-angiotensin inhibitor in
94% and an MRA in 71%.2 We examined the effect of dapagliflozin compared with placebo on
efficacy and safety outcomes according to baseline diuretic therapy and on change in diuretic
requirement and possible markers of volume status over time.
METHODS
Study Design and Criteria
The design and primary results of DAPA-HF have been published.2,3 The Ethics Committee for
each participating institution approved the protocol, and all patients gave written informed consent.
Eligibility for the trial included New York Heart Association class II to IV symptoms, an ejection
fraction of ≤40%, and an elevated NT-proBNP (N-terminal B-type natriuretic peptide) level. For
patients who had been hospitalized within the preceding 12 months, the NT-proBNP threshold was
≥400 pg/mL; for any patient with atrial fibrillation or flutter, the threshold was ≥900 pg/mL; and for
patients who met neither of these criteria, the threshold was ≥600 pg/mL. Investigators were
asked to ensure that patients were optimally treated with pharmacological and device therapy for
HFrEF, in keeping with local guidelines. The protocol advised that an angiotensin-converting
enzyme inhibitor, angiotensin receptor blocker, or sacubitril/valsartan and a β-blocker, as well as
an MRA, should be used at guideline-recommended doses unless contraindicated or not tolerated.
The protocol also stated that in patients taking diuretics, the goal of treatment was achieving
optimal fluid volume status in each individual. The main exclusion criteria included recent
treatment with an SGLT2 inhibitor, symptomatic hypotension or a systolic blood pressure of <95
mm Hg, an estimated glomerular filtration rate of <30 mL·min−1·1.73 m−2, rapidly declining renal
function, or type 1 diabetes mellitus.
Data underlying the findings described in this article may be obtained in accordance with
AstraZeneca’s data-sharing policy.
Trial Procedures
After a 14-day screening period, patients were randomized in a 1:1 fashion to receive dapagliflozin
at a dose of 10 mg once daily or placebo. Randomization was stratified according to diabetes
mellitus status (either a history of diabetes mellitus or a glycated hemoglobin level of ≥6.5% at
screening). Patients were evaluated after randomization at 14 days, 2 and 4 months, and every 4
months thereafter.
Trial Outcomes
The primary outcome was the composite of an episode of worsening HF or cardiovascular death,
whichever occurred first. An episode of worsening HF was either an unplanned hospitalization or
an urgent visit resulting in intravenous therapy for HF. Secondary outcomes included change in
Kansas City Cardiomyopathy Questionnaire total symptom score from baseline to 8 months (a
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lower score equates to worse symptoms) and a composite of worsening renal function and death
resulting from any cause. Safety outcomes included all serious adverse events and specific
adverse events, including those associated with discontinuation of the study drug and other events
of interest such as volume depletion and renal events. Changes in laboratory and clinical findings
from baseline to 8 months were also examined.
Statistical Analysis
We included patients treated and not treated with a diuretic at baseline. Patients treated with a
diuretic were included if they had information on dose. MRAs were not classed as a diuretic for the
purposes of this analysis. Bumetanide 1 mg, torsemide 20 mg, azosemide 60 mg, and etacrynic
acid 100 mg were considered equivalent to furosemide 40 mg intravenously and furosemide 80
mg orally. If at any time the loop diuretic dose was indeterminate, the patient was excluded from
the analyses at that time point only and included again as soon as the dose could be determined.
If a patient was not taking a loop diuretic, the patient was classified as being on 0 mg until he or
she either was started on a loop diuretic or died (at which point the dose was recorded as
missing). The following furosemide-equivalent oral daily dose categories were generated: <40 mg,
40 mg exactly, and >40 mg, in addition to a “no diuretic” category. Patients on a nonloop diuretic
only (eg, a thiazide diuretic alone) were included in the group of <40 mg of furosemide-equivalent
loop diuretic. Only a small number of patients were taking a combination (mostly a loop and
thiazide or thiazide-like diuretic; see Results).
Baseline characteristics were compared across diuretic therapy categories with the use of
ANOVA, Kruskal-Wallis tests, and χ2 tests. Proportional changes in diuretic dose from baseline to
14 days and to 2, 6, 12, and 18 months were modeled with logistic regression. As a sensitivity
analysis, a partial proportional odds model was also used to examine change in diuretic dose at
different time points.
Changes in hematocrit, creatinine, NT-proBNP, systolic blood pressure, and weight were
analyzed with a mixed model for repeated measures (adjusted for baseline values, randomized
treatment, and interaction of treatment and visit, with a random intercept and slope per patient),
and the between-treatment-group differences at 8 months after randomization were presented by
diuretic subgroup as least-square-means difference and 95% CI. Because improvement in clinical
status with any treatment for HFrEF may reduce diuretic requirement, for comparison, we also
examined change in diuretic dose over time in the CHARM trials (Candesartan in Heart Failure
Assessment of Reduction in Mortality and Morbidity) of low left ventricular ejection fraction.4
Time-to-first-event outcomes (the primary composite outcome and its components,
hospitalization for heart failure/urgent heart failure visit or cardiovascular death, worsening renal
function, and death resulting from any cause) were analyzed with Cox regression. Cumulative first
events were displayed with Kaplan-Meier curves. The interaction between diuretic therapy and the
effect of treatment was assessed with the respective statistical model for that measure or outcome
and with a logistic regression model for the safety outcomes. All models were stratified by or
adjusted for diabetes mellitus status and, except in the cases of death resulting from any cause
and the composite worsening renal function end point (the latter included baseline estimated
glomerular filtration rate), previous hospitalization for heart failure. Additional variables included in
adjusted models were age, sex, race, New York Heart Association class, left ventricular ejection
fraction, cause of heart failure, NT-proBNP (log), heart rate, systolic blood pressure, estimated
glomerular filtration rate, atrial fibrillation/flutter, and previous hospitalization for heart failure if not
already included in the model (except for death resulting from any cause). All analyses were
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conducted with STATA version 16 (StataCorp LLC, College Station, TX). A value of P<0.05 was
considered statistically significant.
RESULTS
Of the 4744 patients randomized, 736 (15.5%) were not taking a diuretic, and of the remaining
4008 participants, 3880 had a determinable diuretic dose (expressed as the furosemide-equivalent
dose). Of those receiving a diuretic (n=3880), the largest number (1365 patients; 29.6% of all
analyzed patients and 35.2% of patients receiving a diuretic) were taking a furosemide-equivalent
dose of 40 mg (Table 1). The number taking >40 mg was 1204 (26.1% and 31.0%, respectively),
and the number taking <40 mg or a nonloop diuretic only was 1311 (28.4% and 33.8%,
respectively). The most commonly used loop diuretic among those prescribed a loop diuretic was
furosemide. Bumetanide was used more frequently in patients on a dose of >40 mg furosemide
equivalent than in patients on lower doses of loop diuretic. Overall, 320 (6.9% and 8.2%,
respectively) were taking a combination of diuretics; in most cases (272, 85.0%), this was the
combination of a loop and thiazide or thiazide-like diuretic alone. A similar proportion of patients in
each diuretic group were randomized to dapagliflozin or placebo.














Dose (furosemide equivalent), mg
 Mean in all patients … 16.4±8.7 40 120.6±150.0 57.0±94.4 <0.001
 Mean in patients on loop
diuretic
… 19.1±6.1 … … 59.9±95.9  
 Median in all patients … 20 (10–20) 40 80 (80–120) 40 (20–80) <0.001
 Median in patients on loop
diuretic
… 20 (20–20) … … 40 (20–80)  
Loop diuretic‡, n (%) <0.001
 Azosemide … 47 (4.2) 0 (0.0) 24 (2.0) 71 (1.9)  
 Bumetanide … 0 (0.0) 1 (0.1) 74 (6.1) 75 (2.0)  
 Furosemide … 780 (69.1) 1078 (79.0) 782 (65.0) 2640
(71.4)
 
 Torsemide … 296 (26.2) 282 (20.7) 250 (20.8) 828 (22.4)  
 Combination … 5 (0.4) 4 (0.3) 74 (6.1) 83 (2.2)  
Nonloop diuretic, n (%) … 268 (20.4) 114 (8.4) 121 (10.0) 503 (13.0) <0.001
Randomized to dapagliflozin, n
(%)
372 (50.5) 668 (51.0) 688 (50.4) 582 (48.3) 1938
(49.9)
0.58
Age, y 67.3±10.6 66.8±10.7 66.7±10.6 64.8±11.4 66.1±10.9 <0.001
Female, n (%) 166 (22.6) 326 (24.9) 345 (25.3) 246 (20.4) 917 (23.6) 0.015
Race, n (%) <0.001
 Asian 225 (30.6) 461 (35.2) 187 (13.7) 213 (17.7) 861 (22.2)  
 Black or African American 11 (1.5) 29 (2.2) 86 (6.3) 95 (7.9) 210 (5.4)  
 Other 10 (1.4) 14 (1.1) 22 (1.6) 23 (1.9) 59 (1.5)  
 White 490 (66.6) 807 (61.6) 1070 (78.4) 873 (72.5) 2750
(70.9)
 















Region, n (%) <0.001
 Asia/Pacific 218 (29.6) 456 (34.8) 183 (13.4) 212 (17.6) 851 (21.9)  
 Europe 218 (29.6) 588 (44.9) 707 (51.8) 580 (48.2) 1875
(48.3)
 
 North America 150 (20.4) 146 (11.1) 152 (11.1) 191 (15.9) 489 (12.6)  
 South America 150 (20.4) 121 (9.2) 323 (23.7) 221 (18.4) 665 (17.1)  
NYHA functional classification, n (%) <0.001
 II 588 (79.9) 916 (69.9) 876 (64.2) 731 (60.7) 2523
(65.0)
 
 III 142 (19.3) 384 (29.3) 473 (34.7) 464 (38.5) 1321
(34.0)
 
 IV 6 (0.8) 11 (0.8) 16 (1.2) 9 (0.7) 36 (0.9)  
























32.1±6.3 32.1±6.4 31.0±6.7 29.4±7.1 30.9±6.8 <0.001
Estimated GFR,
mL·min−1·1.73 m−2
70.4±18.6 67.4±19.4 65.0±18.9 62.5±19.7 65.0±19.4 <0.001
Estimated GFR <60
mL·min−1·1.73 m−2, n (%)
216 (29.4) 497 (37.9) 572 (41.9) 575 (47.8) 1644
(42.4)
<0.001
Creatinine, µmol/L 95.8±26.3 100.9±29.1 104.6±28.7 112.8±33.6 105.9±30.8 <0.001
Hematocrit, % 41.5±4.8 41.4±4.8 41.7±5.0 41.2±5.2 41.5±5.0 0.053
Heart rate, bpm 69.9±11.8 71.3±11.6 71.7±11.0 72.8±12.4 71.9±11.7 <0.001
Systolic blood pressure, mm
Hg
123.5±17.2 123.1±16.1 122.1±16.0 119.4±16.2 121.6±16.1 <0.001
Weight, kg 76.2±17.4 75.7±18.1 82.7±19.5 86.4±23.1 81.5±20.7 <0.001
Body mass index, kg/m2 26.7±5.0 26.9±5.3 28.8±5.9 29.8±6.7 28.4±6.1 <0.001
Principal cause of heart failure, n (%) 0.007
 Ischemic 424 (57.6) 781 (59.6) 780 (57.1) 625 (51.9) 2186
(56.3)
 
 Nonischemic 247 (33.6) 436 (33.3) 477 (34.9) 479 (39.8) 1392
(35.9)
 
 Unknown 65 (8.8) 94 (7.2) 108 (7.9) 100 (8.3) 302 (7.8)  
Medical history, n (%)
 Hospitalization for heart
failure
271 (36.8) 606 (46.2) 654 (47.9) 666 (55.3) 1926
(49.6)
<0.001
 Atrial fibrillation 217 (29.5) 477 (36.4) 536 (39.3) 526 (43.7) 1539
(39.7)
<0.001
 Diabetes mellitus 243 (33.0) 494 (37.7) 585 (42.9) 606 (50.3) 1685
(43.4)
<0.001
Device therapy, n (%)
 Implantable cardioverter-
defibrillator§
167 (22.7) 274 (20.9) 326 (23.9) 422 (35.0) 1022
(26.3)
<0.001
 Cardiac resynchronization 46 (6.2) 78 (5.9) 89 (6.5) 116 (9.6) 283 (7.3) 0.001
Other medical therapy, n (%)
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Patient Characteristics
There were several differences between patients in the different diuretic groups (Table 1).
Compared with those not receiving a diuretic, patients in the highest diuretic dose category (>40
mg) were younger; had worse symptoms, functional class, and renal function; had higher NT-
proBNP levels and body mass index and lower left ventricular ejection fraction and systolic blood
pressure; and were more likely to have a history of heart failure hospitalization, atrial fibrillation,
and diabetes mellitus. Hematocrit was similar between groups at baseline. Patients in the highest
diuretic dose category at baseline were more often treated with an MRA and digoxin. The small
group (n=320) of patients taking the combination of a loop and another diuretic had a more severe
profile overall (Table I in the Data Supplement).
Change in Diuretic Dose After Randomization
The mean (SD) furosemide-equivalent dose in patients taking any diuretic was 57.0 (94.4) mg; in
patients taking a loop diuretic, it was 59.9 (95.9) mg, with no statistically significant difference
between treatment groups (Table 2). There was no change in the loop diuretic dose in most
patients at 2 weeks and at 2, 6, 12, and 18 months (97.1%, 91.4%, 83.3%, 77.2%, and 73.6%,
respectively); this was the case in patients randomized to placebo or dapagliflozin. Throughout
follow-up, the mean dose of loop diuretic rose at a similar rate in both treatment arms (Figure 1),
and this was the case regardless of baseline dose (Figure I in the Data Supplement). The findings














 ACE inhibitor or ARB 603 (81.9) 1140 (87.0) 1172 (85.9) 947 (78.7) 3259
(84.0)
<0.001
 Sacubitril-valsartan 91 (12.4) 97 (7.4) 134 (9.8) 148 (12.3) 379 (9.8) <0.001
 β-Blocker 695 (94.4) 1259
(96.0)
1316 (96.4) 1166 (96.8) 3741
(96.4)
0.054
 MRA 425 (57.7) 939 (71.6) 1004 (73.6) 923 (76.7) 2866
(73.9)
<0.001
 Digoxin 80 (10.9) 230 (17.5) 249 (18.2) 304 (25.2) 783 (20.2) <0.001
Glucose-lowering medication, n (%)ǁ
 Biguanide 131 (53.9) 232 (47.0) 317 (54.2) 305 (50.3) 854 (50.7) 0.089
 Sulfonylurea 42 (17.3) 104 (21.1) 135 (23.1) 149 (24.6) 388 (23.0) 0.11
 DPP-4 inhibitor 46 (18.9) 98 (19.8) 76 (13.0) 84 (13.9) 258 (15.3) 0.005
 GLP-1 receptor agonist 1 (0.4) 6 (1.2) 5 (0.9) 8 (1.3) 19 (1.1) 0.63
 Insulin 40 (16.5) 117 (23.7) 157 (26.8) 206 (34.0) 480 (28.5) <0.001
Data are presented as mean±SD or median (interquartile range) for continuous measures and number (percent) for categorical
variables. ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor blocker; DPP-4, dipeptidyl peptidase-4;
GFR, glomerular filtration rate; GLP-1, glucagon-like peptide-1; NYHA, New York Heart Association; KCCQ, Kansas City
Cardiomyopathy Questionnaire; MRA, mineralocorticoid receptor antagonist; and NT-proBNP, N-terminal pro-B-type natriuretic
peptide.
* Patients on a nonloop diuretic only are included in this group (n=183).
† P value for the comparison of no diuretic, <40 mg, 40 mg, and >40 mg.
‡ In patients on a loop diuretic (ie, excluding those on a nonloop diuretic only).
§ Implantable cardioverter-defibrillator or cardiac resynchronization therapy with a defibrillator.
ǁ In patients with a history of diabetes mellitus at baseline; no diuretic, n=243; <40 mg, n=494; 40 mg, n=585; and >40 mg,
n=606.
Table 2. Loop Diuretic Doses and Changes in Loop Diuretic Dose From Baseline (Table view)
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 Placebo Dapagliflozin P Value Odds Ratio (95% CI) l lifl i  l  ti  (  I)
Baseline
 Daily dose (n=3697)*
  Median, mg 40 (20–80) 40 (20–80) 0.35  
  Mean, mg 60.8±96.8 59.0±94.9 0.57  
14 d (n=4595)†
 Daily dose (n=3688)*
  Median, mg 40 (20–80) 40 (20–80) 0.41  
  Mean, mg 60.9±97.5 59.3±97.0 0.62  
 Decrease 32 (1.4) 35 (1.5) 0.72 1.10 (0.67–1.78)
 Increase 40 (1.7) 27 (1.2) 0.11 0.67 (0.41–1.10)
 No change 2222 (96.9) 2239 (97.3) 0.37 1.17 (0.83–1.65)
2 mo (n=4547)†
 Daily dose (n=3630)*
  Median, mg 40 (20–80) 40 (20–80) 0.24  
  Mean, mg 62.2±102.3 59.1±99.1 0.36  
 Decrease 81 (3.6) 117 (5.1) 0.009 1.47 (1.10–1.97)
 Increase 116 (5.1) 76 (3.3) 0.003 0.64 (0.48–0.86)
 No change 2074 (91.3) 2083 (91.5) 0.81 1.02 (0.83–1.26)
6 mo (n=4404)†
 Daily dose (n=3472)*
  Median, mg 40 (20–80) 40 (20–80) 0.019  
  Mean, mg 62.8±104.6 58.9±101.4 0.26  
 Decrease 161 (7.3) 230 (10.4) <0.001 1.49 (1.20–1.84)
 Increase 217 (9.9) 128 (5.8) <0.001 0.56 (0.45–0.70)
 No change 1817 (82.8) 1851 (83.8) 0.37 1.07 (0.91–1.26)
12 mo (n=4044)†
 Daily dose (n=3203)*
  Median, mg 40 (20–80) 40 (20–80) 0.027  
  Mean, mg 65.6±109.4 59.8±104.2 0.13  
 Decrease 176 (8.7) 252 (12.4) <0.001 1.50 (1.22–1.84)
 Increase 285 (14.2) 208 (10.2) <0.001 0.69 (0.57–0.83)
 No change 1551 (77.1) 1572 (77.4) 0.84 1.01 (0.87–1.17)
18 mo (n=2371)†
 Daily dose (n=1880)*
  Median, mg 40 (22.9–80) 40 (20–80) 0.086  
  Mean, mg 71.0±140.1 60.6±119.0 0.084  
 Decrease 122 (10.4) 154 (12.9) 0.055 1.29 (1.00–1.67)
 Increase 184 (15.6) 166 (13.9) 0.24 0.87 (0.69–1.09)
 No change 871 (74.0) 874 (73.2) 0.66 0.95 (0.79–1.15)
Data are presented as mean±SD or median (interquartile range) for continuous measures and number (percent) for categorical
variables.
* Number of patients on a loop diuretic at given time point.
† Number of patients with determinate loop diuretic dose at both time points (including patients on no loop diuretic as 0 mg).
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A small proportion of patients had their dose of diuretic reduced, and this happened more
frequently with dapagliflozin than with placebo (at 6 months, 10.4% versus 7.3%, respectively,
P<0.001; at 12 months, 12.4% versus 8.7%, P<0.001). Conversely, fewer patients in the
dapagliflozin arm compared with the placebo arm had an increase in diuretic dose during follow-
up, although again the proportion of patients in either treatment arm with an increase in diuretic
dose was small (at 6 months, 5.8% versus 9.9%, P<0.001; at 12 months, 10.2% versus 14.2%,
P<0.001). The likelihood of a change in diuretic dose was similar whether a logistic regression or a
proportional odds model was used. In comparison, the findings were very similar in CHARM (Table
II in the Data Supplement).
After an initial change in dose of diuretic, further changes tended to reverse the original
change; for example, when the initial change was an increase in dose, the subsequent change
was more likely to be a decrease (Figure III in the Data Supplement).
Clinical Outcomes According to Baseline Diuretic Treatment
The cumulative incidences of the primary composite outcome, hospitalization or urgent visit for
heart failure, death resulting from cardiovascular causes, and death resulting from any cause were
all lowest in patients not taking any diuretic and highest in those receiving a furosemide-equivalent
dose of >40 mg (Figure IV in the Data Supplement).
The risks of the primary composite outcome and its components (hospitalization or urgent visit
for heart failure and death resulting from cardiovascular causes) were reduced by dapagliflozin
compared with placebo in all patients, whether treated or not treated with a diuretic, and
regardless of dose in patients receiving a diuretic (Table 3 and Figure 2). The single possible
exception to this was in the group of patients taking a combination of a loop and another diuretic at
baseline, although the number of events in this group was small, the 95% CI around the hazard
ratio was wide, and the interaction P value was nonsignificant (Table I in the Data Supplement).
Findings for the components of the primary end point and the other mortality/morbidity outcomes
were consistent.
Figure 1. Change in loop diuretic dose over time in all patients.
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0.57 (0.36–0.92) 0.83 (0.63–1.10) 0.77 (0.60–0.99) 0.7
  Adjusted
HR
0.53 (0.32–0.86) 0.83 (0.63–1.10) 0.76 (0.59–0.98) 0.7
 Hospitalization or urgent HF visit
  No. 28 15 65 54 87 63 131
  Rate 5.6 (3.9–
8.1)
2.8 (1.7–4.6) 7.3 (5.7–
9.3)







0.49 (0.26–0.91) 0.78 (0.55–1.12) 0.68 (0.49–0.94) 0.8
  Adjusted
HR
0.43 (0.22–0.84) 0.77 (0.53–1.11) 0.67 (0.49–0.93) 0.7
 Urgent HF visit
  No. 3 1 7 2 6 2 6
  Rate 0.6 (0.2–
1.8)
0.2 (0.0–1.3) 0.8 (0.4–
1.6)
0.2 (0.1–0.8) 0.6 (0.3–
1.3)




0.28 (0.03–2.70) 0.27 (0.06–1.32) 0.33 (0.07–1.63) 0.84
  Adjusted
HR
… 0.22 (0.04–1.27) 0.29 (0.05–1.56) 0.6
 Cardiovascular death
  No. 25 16 62 54 76 68 102
  Rate 4.8 (3.2–
7.1)
2.9 (1.8–4.7) 6.6 (5.1–
8.4)
5.5 (4.2–7.1) 7.5 (6.0–
9.4)




0.61 (0.32–1.14) 0.82 (0.57–1.18) 0.87 (0.63–1.21) 0.9
  Adjusted
HR
0.60 (0.31–1.14) 0.85 (0.58–1.23) 0.87 (0.63–1.21) 0.9
 Hospitalization for HF or cardiovascular death
  No. 44 27 106 95 132 109 195
  Rate 8.7 (6.5–
11.7)













0.57 (0.35–0.92) 0.84 (0.64–1.11) 0.78 (0.61–1.01) 0.7
  Adjusted
HR
0.52 (0.32–0.87) 0.84 (0.64–1.12) 0.77 (0.60–1.00) 0.7










Placebo Dapagliflozin Placebo Dapagliflozin Placebo Dapagliflozin Placeb
 Worsening renal function
  Number 4 2 3 5 8 5 22
  Rate 0.8 (0.3–
2.2)
0.4 (0.1–1.5) 0.3 (0.1–
1.0)
0.5 (0.2–1.3) 0.8 (0.4–
1.7)




0.49 (0.09–2.69) 1.63 (0.39–6.81) 0.59 (0.19–1.82) 0.6
  Adjusted
HR
0.11 (0.00–2.49) 2.10 (0.45–9.72) 0.57 (0.18–1.80) 0.7
 Death resulting from any cause
  No. 31 23 71 64 95 78 123
  Rate 5.9 (4.2–
8.4)
4.1 (2.8–6.2) 7.5 (6.0–
9.5)







0.71 (0.41–1.21) 0.86 (0.61–1.20) 0.80 (0.59–1.08) 0.9
  Adjusted
HR




3.1±1.1 5.8±1.1 2.8±0.8 4.6±0.8 2.7±0.8 7.6±0.8 5.3±0.















21 (5.8) 8 (2.2) 31 (4.8) 27 (4.0) 46 (6.8) 44 (6.4) 68 (11.
Other changes at 8 mo
 Hematocrit,
%
−0.3±0.2 2.6±0.2 −0.3±0.1 2.4±0.1 −0.1±0.1 2.1±0.1 −0.2±0
  Difference 2.9 (2.5 to 3.4) 2.7 (2.3 to 3.1) 2.2 (1.8 to 2.5) 2.3
 SBP, mm Hg −2.2±0.8 −3.3±0.8 −1.0±0.6 −2.6±0.6 0.4±0.6 −1.6±0.6 0.1±0.
  Difference −1.1 (−3.3 to 1.0) −1.6 (−3.2 to −0.1) −2.0 (−3.5 to −0.4) −0.7
 Weight, kg −0.01±0.19 −0.98±0.19 0.22±0.14 −1.06±0.14 −0.08±0.14 −0.89±0.14 0.07±0.
  Difference −0.97 (−1.40 to −0.54) −1.28 (−1.62 to −0.94) −0.81 (−1.22 to −0.39) −0.58 
 Creatinine,
mg/dL
0.05±0.01 0.07±0.01 0.04±0.01 0.05±0.01 0.03±0.01 0.07±0.01 0.06±0.
  Difference 0.02 (−0.01 to 0.05) 0.01 (−0.02 to 0.03) 0.04 (0.01 to 0.06) 0.02 
 NT-proBNP,
pg/mL
−65±149 −194±146 265±112 −173±110 −10±110 −365±108 −22±11
  Difference −126 (−395 to 143) −437 (−740 to −134) −360 (−713 to −6) −132
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When the effect of randomized treatment was examined as a function of change in diuretic
dose from baseline to 6 months (decrease, increase, or no change), the incidence of the primary
composite outcome was lower with dapagliflozin compared with placebo in each diuretic dose
change group (P for interaction=0.27; Figure V in the Data Supplement).
The placebo-corrected improvement in Kansas City Cardiomyopathy Questionnaire total
symptom score was consistent in patients treated with dapagliflozin, regardless of diuretic
treatment or no diuretic treatment or diuretic dose (Table 3).
Because the number of patients experiencing the prespecified renal composite outcome was
small overall, meaningful interpretation of the subgroups was difficult. However, the rate of this
outcome was highest in the patients on the highest diuretic dose and did not differ between
dapagliflozin and placebo in that diuretic dose group.
Safety
The frequency of volume depletion, renal adverse events, and study drug discontinuation as a
result of an adverse event varied according to background diuretic therapy in the placebo arm.
Rates are per 100-patient years. Changes from baseline to 8 months are shown as estimate±standard error. All unadjusted
models include prior heart failure hospitalization (except for death resulting from any cause and worsening renal function) and
trial stratification. Unadjusted model for worsening renal function includes estimated glomerular filtration rate. All adjusted
models include age, sex, race, New York Heart Association functional class, left ventricular ejection fraction, heart failure cause,
NT-proBNP (log), heart rate, systolic blood pressure, estimated glomerular filtration rate, atrial fibrillation, and (except for death
resulting from any cause) prior heart failure hospitalization. HR indicates hazard ratio; KCCQ TSS, Kansas City Cardiomyopathy
Questionnaire total symptom score; NT-proBNP, N-terminal pro-B-type natriuretic peptide; and SBP, systolic blood pressure.
* Patients on a nonloop diuretic only are included in this group (n=183).
Figure 2. Forest plot of efficacy outcomes according to diuretic therapy at baseline.
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The rates of all adverse outcomes of interest were lower in patients not treated with a diuretic at
baseline compared with patients treated with a diuretic. Among patients treated with a diuretic at
baseline, the placebo rate of each adverse outcome was highest in patients on a dose of >40 mg
furosemide equivalent (Table 3).
When the randomized treatment arms were compared, volume depletion and renal adverse
events were significantly less common in patients allocated to dapagliflozin compared with those
randomized to placebo in patients not taking diuretics at baseline. In patients taking diuretics,
volume depletion was slightly more common with dapagliflozin than with placebo in patients in the
higher-dose diuretic groups. Other adverse effects were not different, and there was no difference
between treatment groups in study drug discontinuation for adverse events.
Other Measures of Interest
From baseline to 8 months, the placebo-corrected increases in hematocrit and creatinine and
decreases in systolic blood pressure and weight with dapagliflozin were similar in patients
receiving and those not receiving diuretics at baseline (Table 3 and Figure 3). Although the
decrease in NT-proBNP was numerically greater in patients receiving diuretics, the variance in this
measure was large, and the difference was not statistically significant.
In a comparison across the diuretic dose groups, none of the placebo-corrected changes with
dapagliflozin differed significantly, although the changes tended to be smallest in the highest
diuretic dose group.
Figure 3. Changes in laboratory and clinical measures according to diuretic therapy at baseline.
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The elevation in hematocrit with dapagliflozin was sustained, regardless of dose of loop diuretic
(Table 3 and Figure 3). This persisted regardless of whether the dose of conventional diuretic was
decreased, was increased, or remained the same at 6 and 12 months (Figure VI in the Data
Supplement).
DISCUSSION
The key finding of the present analyses is that the benefits of dapagliflozin in DAPA-HF were
obtained regardless of the use of background diuretic therapy or dose of diuretic therapy.
Likewise, the tolerability and safety profile of dapagliflozin compared with placebo was similar
regardless of concomitant treatment with a conventional diuretic or dose of conventional diuretic.
Last, most patients did not have a change in dose of diuretic during follow-up, and the mean daily
dose of diuretic did not differ between the dapagliflozin and placebo groups.
The use of diuretic therapy at baseline in DAPA-HF was in keeping with other reports in large
cohorts of patients with HFrEF, predominantly in New York Heart Association class II and III. In
DAPA-HF, 16% of patients were not treated with a diuretic at baseline (not counting an MRA as a
diuretic), a proportion consistent with that reported in other recent trials and registries.5–10
Among all patients randomized in DAPA-HF, 81% were treated with a loop diuretic, also in
keeping with other studies.11–15 In DAPA-HF, the mean and median furosemide-equivalent doses
were 60 and 40 mg, respectively, with the largest proportion receiving a daily dose of 40 mg
(35.2% of patients taking any diuretic). In PARADIGM-HF (Prospective Comparison of ARNI
[Angiotensin Receptor Neprilysin Inhibitor] With ACEI to Determine Impact on Global Mortality and
Morbidity in Heart Failure), the mean daily dose was 49 mg, and 60.6% of patients were treated
with between 20 and 40 mg at baseline, although the dose conversion calculation was different in
this study.11 Additional information on loop diuretic dosing is hard to obtain; however, in the
CHARM HFrEF trials, in the recent HFrEF registry from the Netherlands, and in the HF-ACTION
trial (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training), the median
dose was also 40 mg.4,12,15
Despite notable differences in patient characteristics according to use of diuretic at baseline
(and according to dose of diuretic among those taking diuretics), the benefit of dapagliflozin was
consistent in all the diuretic groups studied. As expected, patients not receiving diuretics had a
more favorable clinical profile and were at lowest risk of the clinical outcomes evaluated. The
converse was true of patients in the highest diuretic dose category. Although the magnitude of the
benefit from dapagliflozin appeared to be larger in patients not treated with a diuretic, there were
relatively few patients in this group, and the CIs around the point estimate for the effect of
treatment were wide. A statistical test for interaction between background diuretic therapy and the
effect of randomized treatment was not significant. In addition, there was no suggestion of any
dose response in relation to baseline diuretic therapy, and diuretic dose group did not modify the
effect of randomized treatment in an interaction test. Consistent with this, the effect of dapagliflozin
on other measures such as systolic blood pressure, weight, creatinine, and hematocrit did not vary
substantially between patients treated and those not treated with a diuretic and across the diuretic
dose groups.
The tolerability and safety of dapagliflozin were also consistent in patients treated and those
not treated with diuretics and across the diuretic dose groups studied. In this analysis, our focus
was on the prespecified adverse events related to volume depletion and renal dysfunction.
Adverse events related to volume depletion were relatively infrequent overall but, as expected,
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were more common in patients receiving higher doses of diuretic (ranging from 5.3% to 8.9% in
the placebo arm, from the lowest to highest diuretic dose group). These events were numerically
slightly more common in patients randomly assigned to dapagliflozin compared with those
assigned to placebo, although the excess was small (0.2% in the lowest diuretic dose group, 3.1%
in the middle dose group, and 1.6% in the highest dose group). More surprisingly, the rate of
adverse events related to volume depletion was as high in the patients not receiving diuretic at
baseline as in patients in the highest diuretic dose group (8.5% and 8.9% in the placebo arms,
respectively). In patients not receiving diuretic at baseline, the rate of adverse events related to
volume depletion after randomization was lower in patients assigned to dapagliflozin than in those
assigned to placebo. Similar patterns were seen for renal adverse events in the placebo group in
relation to baseline diuretic therapy (more common with increasing diuretic dose, more common in
patients not taking diuretics than in those in the lowest diuretic dose group in the placebo arm).
However, renal adverse events were generally less common in patients assigned to dapagliflozin
compared with those assigned to placebo, a pattern opposite that observed for volume depletion.
Few patients stopped study drug for an adverse event, generally <5% in any subgroup except
patients taking >40 mg/d furosemide or equivalent, and in that subgroup, the proportion was 7.6%
in the placebo group and 6.7% in the dapagliflozin group.
Although our findings go some way to assuaging the hypothetical safety concerns about
combining SGLT2 inhibitors with conventional diuretics (and MRAs) in HFrEF, they do not directly
address the reported diuretic action of SGLT2 inhibitors. However, our analyses provide evidence
that the combination of dapagliflozin with conventional diuretics in DAPA-HF did not have a major
impact on the use of loop diuretics in the majority of patients. The mean dose of furosemide did
not differ between the dapagliflozin and placebo group during follow-up, and most patients did not
change their diuretic dose. A small proportion did have an increase or decrease in dose, and an
increase was less likely and a decrease was more likely in the dapagliflozin arm compared with
the placebo arm (between-treatment difference in proportion was <5% at all time points
examined). Moreover, this small difference was similar to that seen with other treatments that
improve symptoms and reduce worsening of heart failure status over time but do not have diuretic
properties, as illustrated in the comparison with CHARM and in a report from the PARADIGM-HF
trial.11 These findings do not preclude a diuretic effect of dapagliflozin (and clinical benefit related
to such an action), and previous studies have shown a short-lived initial natriuresis with SGLT2
inhibitors with restoration of a new sodium volume steady state within days to weeks of treatment
starting.16–19 In addition, the increased electrolyte-free water excretion induced by SGLT2
inhibitors and possible enhanced peripheral sodium storage are other factors that may contribute
to the impact of these agents on whole-body sodium volume status.20,21 However, the similar
effects of dapagliflozin in patients with chronic kidney disease and in those without diabetes
mellitus, 2 groups who should have had less diuretic effect from SGLT2 inhibition, argue for
additional mechanisms of benefit.2 Although the increase in hematocrit seen with SGLT2 inhibitors
is also often said to reflect a diuretic-induced reduction in blood volume, this assumption may be
overly simplistic. The increase in hematocrit in DAPA-HF was similar, regardless of use of diuretic
at baseline or baseline loop diuretic dose, and was seen despite rates of volume depletion similar
to those observed in the placebo group. The elevation in hematocrit also persisted in individuals
with a reduction in loop diuretic dose at both 6 and 12 months. Collectively, these findings support
the notion that factors other than hemoconcentration such as augmentation of erythropoiesis may
account for the sustained increase in hematocrit seen with dapagliflozin. A reduction in circulating
levels of hepcidin, an increase in levels of the hepcidin inhibitor erythroferrone, and an increase in
erythropoietin have been shown to occur with the use of SGLT2 inhibitors.22–24
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The study has some limitations. This was not a prespecified analysis. Furosemide-equivalent
loop diuretic doses were not available for all patients. Dose changes were examined at specified
time points, and fluctuations in doses in between these time points were not accounted for in this
analysis. We did not have data on other markers of natriuresis and diuresis such as urine volumes
and urinary sodium excretion. Our results apply only to ambulatory patients with HFrEF
predominantly in New York Heart Association classes II and III who fulfilled the trial inclusion and
exclusion criteria and received modest doses of conventional diuretic therapy. We do not know
what the efficacy and safety of dapagliflozin might be in different patients receiving a different
treatment in a different setting.
Conclusions
We found that the benefits of dapagliflozin were obtained regardless of background diuretic
therapy and across the range of background doses of diuretic used in DAPA-HF. The tolerability
and safety of dapagliflozin were similar regardless of whether patients were treated or not treated
with a standard diuretic and dose of conventional diuretic. Treatment with dapagliflozin did not
lead to a change in mean dose of background diuretic therapy in most trial participants.
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